Search Results - "Manegold, C."

Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL) by Reck, M., von Pawel, J., Zatloukal, P., Ramlau, R., Gorbounova, V., Hirsh, V., Leighl, N., Mezger, J., Archer, V., Moore, N., Manegold, C.

“…Bevacizumab, the anti-vascular endothelial growth factor agent, provides clinical benefit when combined with platinum-based chemotherapy in first-line advanced…”
Get full text

Bone matters in lung cancer by Brodowicz, T., O'Byrne, K., Manegold, C.

“…Bone metastases are a significant and undertreated clinical problem in patients with advanced lung cancer. We reviewed the incidence of bone metastases and…”
Get full text

ROS1 fusions in Chinese patients with non-small-cell lung cancer by Cai, W., Li, X., Su, C., Fan, L., Zheng, L., Fei, K., Zhou, C., Manegold, C., Schmid-Bindert, G.

“…To determine the prevalence and clinicopathological features of ROS1 fusions in Chinese patients with non-small-cell lung cancer (NSCLC). Formalin-fixed and…”
Get full text

Clinical and biochemical features of aromatic L-amino acid decarboxylase deficiency by Brun, L, Ngu, L H, Keng, W T, Ch'ng, G S, Choy, Y S, Hwu, W L, Lee, W T, Willemsen, M A A P, Verbeek, M M, Wassenberg, T, Régal, L, Orcesi, S, Tonduti, D, Accorsi, P, Testard, H, Abdenur, J E, Tay, S, Allen, G F, Heales, S, Kern, I, Kato, M, Burlina, A, Manegold, C, Hoffmann, G F, Blau, N

“…To describe the current treatment; clinical, biochemical, and molecular findings; and clinical follow-up of patients with aromatic l-amino acid decarboxylase…”
Get full text

Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? by Schmid-Bindert, G., Henzler, Thomas, Chu, T. Q., Meyer, M., Nance, J. W., Schoepf, U. J., Dinter, D. J., Apfaltrer, P., Krissak, R., Manegold, C., Schoenberg, S. O., Fink, C.

“…Objectives To investigate the correlation between maximum standardized uptake value (SUV max ) of 18 FDG PET-CT and iodine-related attenuation (IRA) of dual…”
Get full text

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer by Novello, S., Torri, V., Grohe, C., Kurz, S., Serke, M., Wehler, T., Meyer, A., Ladage, D., Geissler, M., Colantonio, I., Cauchi, C., Stoelben, E., Ceribelli, A., Kropf-Sanchen, C., Valmadre, G., Borra, G., Schena, M., Morabito, A., Santo, A., Gregorc, V., Chiari, R., Reck, M., Schmid-Bindert, G., Folprecht, G., Griesinger, F., Follador, A., Pedrazzoli, P., Bearz, A., Caffo, O., Dickgreber, N.J., Irtelli, L., Wiest, G., Monica, V., Porcu, L., Manegold, C., Scagliotti, G.V.

“…Several strategies have been investigated to improve the 4% survival advantage of adjuvant chemotherapy in early-stage non-small-cell lung cancer (NSCLC). In…”
Get full text

Malignant pleural mesothelioma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up by Manegold, C

Get full text

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer by Manegold, C., van Zandwijk, N., Szczesna, A., Zatloukal, P., Au, J.S.K., Blasinska-Morawiec, M., Serwatowski, P., Krzakowski, M., Jassem, J., Tan, E.H., Benner, R.J., Ingrosso, A., Meech, S.J., Readett, D., Thatcher, N.

“…This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy…”
Get full text

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975 by Efficace, F, Bottomley, A, Smit, EF, Lianes, P, Legrand, C, Debruyne, C, Schramel, F, Smit, HJ, Gaafar, R, Biesma, B, Manegold, C, Coens, C, Giaccone, G, Van Meerbeeck, J

“…Background: The aim of this prognostic factor analysis was to investigate if a patient's self-reported health-related quality of life (HRQOL) provided…”
Get full text

Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”: [Annals of Oncology 33 (2022) 57-66] by Novello, S., Torri, V., Grohe, C., Kurz, S., Serke, M., Wehler, T., Meyer, A., Ladage, D., Geissler, M., Colantonio, I., Cauchi, C., Stoelben, E., Ceribelli, A., Kropf-Sanchen, C., Valmadre, G., Borra, G., Schena, M., Morabito, A., Santo, A., Gregorc, V., Chiari, R., Reck, M., Schmid-Bindert, G., Folprecht, G., Griesinger, F., Follador, A., Pedrazzoli, P., Bearz, A., Caffo, O., Dickgreber, N.J., Irtelli, L., Wiest, G., Monica, V., Porcu, L., Manegold, C., Scagliotti, G.V.

Get full text

Sunitinib in metastatic thymic carcinomas: Laboratory findings and initial clinical experience by Ströbel, P, Bargou, R, Wolff, A, Spitzer, D, Manegold, C, Dimitrakopoulou-Strauss, A, Strauss, L, Sauer, C, Mayer, F, Hohenberger, P, Marx, A

“…Background: Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is a multi-targeted tyrosine…”
Get full text

Antiangiogenic Therapy with Mammalian Target of Rapamycin Inhibitor RAD001 (Everolimus) Increases Radiosensitivity in Solid Cancer by MANEGOLD, Philipp C, PARINGER, Carmen, KULKA, Ulrike, KRIMMEL, Klaus, EICHHORN, Martin E, WILKOWSKI, Ralf, JAUCH, Karl-Walter, GUBA, Markus, BRUNS, Christiane J

“…Purpose: Radiotherapy exerts direct antivascular effects in tumors and also induces a proangiogenic stress response in tumor cells via the phosphoinositide…”
Get full text

Aromatic l-amino acid decarboxylase deficiency: clinical features, drug therapy and follow-up by Manegold, C, Hoffmann, G. F, Degen, I, Ikonomidou, H, Knust, A, Laaß, M. W, Pritsch, M, Wilichowski, E, Hörster, F

“…Background Aromatic l-amino acid decarboxylase (AADC) deficiency is a disorder of biogenic amine metabolism resulting in generalized combined deficiency of…”
Get full text

Statistical controversies in clinical research: futility analyses in oncology–lessons on potential pitfalls from a randomized controlled trial by Lesaffre, E., Edelman, M.J., Hanna, N.H., Park, K., Thatcher, N., Willemsen, S., Gaschler-Markefski, B., Kaiser, R., Manegold, C.

“…Pre-planned futility analyses are commonly used in oncology studies. The LUME-Lung 2 study (NCT00806819; 1199.14) was stopped early based on a pre-planned,…”
Get full text

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma by Manegold, C., Symanowski, J., Gatzemeier, U., Reck, M., von Pawel, J., Kortsik, C., Nackaerts, K., Lianes, P., Vogelzang, N. J.

“…Background:: A phase III trial in patients with malignant pleural mesothelioma demonstrated a survival advantage for pemetrexed plus cisplatin compared with…”
Get full text

Malignant peritoneal mesothelioma—Results from the International Expanded Access Program using pemetrexed alone or in combination with a platinum agent by Carteni, G, Manegold, C, Garcia, G. Martin, Siena, S, Zielinski, C.C, Amadori, D, Liu, Y, Blatter, J, Visseren-Grul, C, Stahel, R

“…Abstract Aim Peritoneal mesothelioma (PM) has rarely been studied. The Expanded Access Program (EAP) provided access to 109 patients with PM. Methods This was…”
Get full text

Prognostic and predictive factors in a randomized phase III trial comparing cisplatin–pemetrexed versus cisplatin–gemcitabine in advanced non-small-cell lung cancer by Syrigos, K.N., Vansteenkiste, J., Parikh, P., von Pawel, J., Manegold, C., Martins, R.G., Simms, L., Sugarman, K.P., Visseren-Grul, C., Scagliotti, G.V.

“…Baseline patient and disease characteristics are investigated in non-small-cell lung cancer (NSCLC) in an effort to predict response to treatment and optimize…”
Get full text

Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules by Körner, A, Mudduluru, G, Manegold, C, Allgayer, H

“…Background: Enzastaurin (Enz) is a serine/threonine kinase inhibitor blocking protein kinase C (PKC) β /AKT pathway. However, an ability of this compound to…”
Get full text

Thymidylate synthase gene variations: predictive and prognostic markers by Lurje, Georg, Manegold, Philipp C, Ning, Yan, Pohl, Alexandra, Zhang, Wu, Lenz, Heinz-Josef

“…Since its introduction more than 50 years ago by Heidelberger et al., the fluoropyrimidine 5-fluorouracil (5-FU) has remained the mainstay of therapeutic…”
Get full text

Talactoferrin alfa versus placebo in patients with refractory advanced non-small-cell lung cancer (FORTIS-M trial) by Chang, A., Manegold, C., Douillard, J.-Y., Malik, R., Giaccone, G., Begbie, S., Jennens, R., Tzekova, V., Couture, F., Hirsh, V., Burkes, R., Sangha, R., Ambrus, M., Janaskova, T., Musil, J., Jakesova, J., Roubec, J., Vanasek, J., Barlesi, F., Bennouna-Louridi, J., Chouaid, C., Robinet, G., Souquet, P.-J., Spaeth, D., Schott, R., Lena, H., Baize, N., Molinier, O., Fuchs, F., Marschner, N., Schuette, W., Syrigos, K., Papandreou, C., Bocskei, C., Juhasz, E., Losonczy, G., Mark, Z., Molnar, I., Papai-Szekely, Z., Tehenes, S., Vinkler, I., Maru, A., Pathak, A., Prasad, S.V.S.S., Kilara, N., Gorijavolu, D., John, S., Amoroso, D., Bajetta, E., Bonetti, A., Maio, M., Passalacqua, R., Bitina, M., Brize, A., Purkalne, G., Skrodele, M., Samson-Fernando, M.C., Jassem, J., Koralewski, P., Cebotaru, C., Ganea-Motan, D.E., Ianuli, C.H., Manolescu, I.G., Udrea, A., Burdaeva, O., Filippov, A., Lazarev, S., Tan, Y.O., Bastus Piulats, R., Garcia-Foncillas, J., Valdivia, J., de Castro, J., Lee, J.-S., Lee, J.S., Shin, S.W., Kim, Y.-C., Chang, G.-C., Goan, Y.-G., Kuo, H.-P., Demir, G., Crawford, J., Giaccone, G., Agarwal, M., Pandit, S., Araujo, R., Vrindavanam, N., Bonomi, P., Wade, J., Camidge, R., Hill, D., Rarick, M., Flynn, P., Savin, M., Richards, D., Dangoor, A., Summers, Y., Rankin, E., Rowley, K., Kristeleit, H., Taylor, P.

“…Talactoferrin alfa is an oral dendritic cell (DC)-mediated immunotherapy (DCMI). We tested whether talactoferrin was superior to placebo in advanced…”
Get full text